Market Report Source

Overview

Introduction
The lack of differentiation between overactive bladder agents has led manufacturers to turn to large-scale marketing efforts in an attempt to gain market share. Given the relatively small marketing capabilities of IDEV and Esprit, they may have difficulty penetrating high-prescribing urology and primary care practices compared to its larger rivals, thus slowing Sanctura XR’s near-term potential.

Scope
Analyzes the commercial potential for IDEV’s Sanctura XR, a recently-approved next-generation OAB agent
Datamonitor interviewed twenty-four urologists regarding trends in the treatment of OAB and the potential role of next-generation Sanctura XR

Highlights
Based on the data from the Phase II trial, we anticipate that once-daily Sanctura XR will demonstrate a safety and efficacy profile comparable to the original twice-daily Sanctura formulation and support its FDA approval in mid/late 2007.

Interviewed physicians indicated that all currently marketed OAB products have comparable safety and efficacy profiles and, as the last once-daily OAB option to come to market, if approved, Sanctura XR would not dramatically impact their OAB prescribing habits given the crowded OAB market.

Reasons to Purchase
Understand the commercial potential for Sanctura XR in the treatment of OAB through in-depth analysis based on interviews with leading experts
Anticipate likely changes in the future market dynamics for overactive bladder agents given the entry of a new market player

Table of Contents

SUMMARY

Last-to-market Sanctura XR unlikely to make an impact in crowded overactive bladder market

INDEVUS PHARMACEUTICALS

Overview

OVERACTIVE BLADDER

Overview

Pharmacotherapy dominated by anticholinergic agents

Wide variety of long-acting once-daily OAB agents available

Improved dosing profile of Sanctura XR aims to boost IDEV’s OAB franchise

FACTORS AFFECTING THE POTENTIAL FOR SANCTURA XR

Little differentiation versus available options likely to diminish Sanctura XR’s potential

Can David compete with multiple Goliaths in crowded OAB market?

DATAMONITOR SANCTURA XR FORECAST

Based on small Phase II and proven technology, FDA approval appears likely

Even if approved, Sanctura XR not likely to make a splash in crowded OAB market

Agents with novel mechanisms of action may change future treatment of OAB

APPENDIX

Supplementary data

Datamonitor Healthcare

Disclosure information

Ask the analyst

List of Tables

Table 1: Near-term IDEV Milestones

Table 2: Currently marketed branded OAB agents

Table 3: Forecast US Sanctura / Sanctura XR franchise revenues 2006-2010

Table 4: Pipeline OAB agents

Table 5: OAB Model 2006-2010